BERKELEY, Calif., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced Rachel Haurwitz, Ph.D., Caribou's president and chief executive officer, is scheduled to participate in the following investor conferences:
- Guggenheim Oncology Conference 2023, New York City
February 9, 2023, 10:45 am EST
Webcast
- SVB Securities Global Biopharma Conference, virtual
February 14, 2023, 5:00 pm EST
Webcast
- Citi's 2023 Oncology Leadership Summit, virtual
February 22, 2023, 2:00 pm EST
Webcast to be made available on Events page
For more information, visit the Events page on Caribou's website. Webcasts will be available on the Caribou website for 30 days after the event.
About Caribou's Novel Next-Generation CRISPR Platform
CRISPR genome editing uses easily designed, modular biological tools to make DNA changes in living cells. There are two basic components of Class 2 CRISPR systems: the nuclease protein that cuts DNA and the RNA molecule(s) that guide the nuclease to generate a site-specific, double-stranded break, leading to an edit at the targeted genomic site. CRISPR systems are capable of editing unintended genomic sites, known as off-target editing, which may lead to harmful effects on cellular function and phenotype. In response to this challenge, Caribou has developed CRISPR hybrid RNA-DNA guides (chRDNAs; pronounced "chardonnays") that direct substantially more precise genome editing compared to all-RNA guides. Caribou is deploying the power of its Cas12a chRDNA technology to carry out high efficiency multiple edits, including multiplex gene insertions, to develop CRISPR-edited therapies.
About Caribou Biosciences, Inc.
Caribou Biosciences is a clinical-stage CRISPR genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company's genome-editing platform, including its proprietary Cas12a chRDNA technology, enables superior precision to develop cell therapies that are specifically engineered for enhanced persistence. Caribou is advancing a pipeline of off-the-shelf CAR-T and CAR-NK cell therapies for the treatment of patients with hematologic malignancies and solid tumors.
For more information about Caribou, visit and follow the company @CaribouBio.
"Caribou Biosciences" and the Caribou logo are registered trademarks of Caribou Biosciences, Inc.
Caribou Biosciences Contacts:
Investors:
Amy Figueroa, CFA
afigueroa@cariboubio.com
Media:
Peggy Vorwald, Ph.D.
pvorwald@cariboubio.com
Investors and Media:
Elizabeth Wolffe, Ph.D., and Sylvia Wheeler
Wheelhouse LSA
lwolffe@wheelhouselsa.com
swheeler@wheelhouselsa.com
加利福尼亚州伯克利,2023年2月1日(环球网)--领先的临床阶段CRISPR基因组编辑生物制药公司Cariou Biosciences,Inc.(纳斯达克市场代码:CRBU)今天宣布,Cariou生物科学公司首席执行官兼首席执行官雷切尔·豪尔维茨博士将参加以下投资者会议:
- 2023年古根海姆肿瘤学会议,纽约市
2023年2月9日美国东部时间上午10:45
网播
- SVB证券全球生物医学大会、虚拟
美国东部时间2023年2月14日下午5:00
网播
- 花旗2023年肿瘤学领导力峰会、虚拟
美国东部时间2023年2月22日下午2:00
网络直播将在活动页面上提供
欲了解更多信息,请访问Cariou网站上的活动页面。活动结束后30天内,Cariou网站将提供网络直播。
关于Cariou的新一代CRISPR平台
CRISPR基因组编辑使用易于设计的模块化生物学工具来改变活细胞中的DNA。第2类CRISPR系统有两个基本组件:切割DNA的核酸酶蛋白质和引导核酸酶产生位点特异性双链断裂的RNA分子,导致目标基因组位点的编辑。CRISPR系统能够编辑非预期的基因组位置,即所谓的非靶标编辑,这可能会对细胞功能和表型产生有害影响。为了应对这一挑战,Cariou开发了CRISPR杂交RNA-DNA指南(chRDNA;发音为“Chardonnays”),与全RNA指南相比,该指南指导的基因组编辑要精确得多。驯鹿正在利用其Cas12a chRDNA技术的力量进行高效的多重编辑,包括多重基因插入,以开发CRISPR编辑的疗法。
关于Cariou生物科学公司
驯鹿生物科学公司是一家临床阶段的CRISPR基因组编辑生物制药公司,致力于为患有毁灭性疾病的患者开发变革性疗法。该公司的基因组编辑平台,包括其专有的Cas12a chRDNA技术,使其能够实现卓越的精度,以开发专门为增强持久性而设计的细胞疗法。驯鹿正在推进一系列现成的CAR-T和CAR-NK细胞疗法,用于治疗血液系统恶性肿瘤和实体瘤患者。
欲了解更多有关Cariou的信息,请访问并关注公司@CariouBio。
“Cariou Biosciences”和Cariou标识是Cariou Biosciences,Inc.的注册商标。
驯鹿生物科学公司联系人:
投资者:
艾米·菲格罗亚,CFA
邮箱:afigueroa@caribouBio.com
媒体:
佩吉·沃瓦尔德,博士。
邮箱:pvorwald@caribouBio.com
投资者和媒体:
伊丽莎白·沃尔夫博士和西尔维娅·惠勒
惠尔豪斯LSA
邮箱:lwolffe@whelhouselsa.com
邮箱:seweler@whelhouselsa.com